Warning: The NCBI web site requires JavaScript to function. more...
State policy influence on the early diffusion of buprenorphine in community treatment programs.
Ducharme LJ, Abraham AJ.
Subst Abuse Treat Prev Policy. 2008 Jun 20;3:17.
Related citations
Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication.
Wallack SS, Thomas CP, Martin TC, Chilingerian J, Reif S.
J Behav Health Serv Res. 2010 Jan;37(1):64-78. Epub 2008 Jul 31.
Buprenorphine diffusion: the attitudes of substance abuse treatment counselors.
Knudsen HK, Ducharme LJ, Roman PM, Link T.
J Subst Abuse Treat. 2005 Sep;29(2):95-106.
Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.
Friedmann PD, Jiang L, Alexander JA.
J Behav Health Serv Res. 2010 Jul;37(3):322-37. Epub 2009 Mar 19.
Consensus statement on office-based treatment of opioid dependence using buprenorphine.
Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR.
J Subst Abuse Treat. 2004 Sep;27(2):153-9. Review.
Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
Turner BJ, Laine C, Lin YT, Lynch K.
Arch Intern Med. 2005 Aug 8-22;165(15):1769-76.
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
Knudsen HK, Abraham AJ, Johnson JA, Roman PM.
J Subst Abuse Treat. 2009 Oct;37(3):307-12. Epub 2009 Jul 3.
Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors.
Knudsen HK, Ducharme LJ, Roman PM.
J Subst Abuse Treat. 2006 Jun;30(4):363-73.
Buprenorphine for office-based treatment of patients with opioid addiction.
Manlandro JJ Jr.
J Am Osteopath Assoc. 2005 Jun;105(6 Suppl 3):S8-13. Review.
Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
Koch AL, Arfken CL, Schuster CR.
Drug Alcohol Depend. 2006 Jul 27;83(3):274-8. Epub 2006 Jan 18.
Buprenorphine for office-based practice: consensus conference overview.
Kosten TR, Fiellin DA; U.S. National Buprenorphine Implementation Program.
Am J Addict. 2004;13 Suppl 1:S1-7. Review.
Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S.
Ann Fam Med. 2007 Mar-Apr;5(2):146-50.
Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care.
Schackman BR, Merrill JO, McCarty D, Levi J, Lubinski C.
Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S247-53. Review.
Counseling buprenorphine patients: information and treatment approaches for counselors.
McCann MJ.
J Psychoactive Drugs. 2004 May;Suppl 2:139-46.
Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
Stock C, Shum JH.
J Pain Palliat Care Pharmacother. 2004;18(3):35-54. Review.
Using buprenorphine for outpatient opioid detoxification.
J Am Osteopath Assoc. 2007 Sep;107(9 Suppl 5):ES11-6. Review.
Availability of addiction medications in private health plans.
Horgan CM, Reif S, Hodgkin D, Garnick DW, Merrick EL.
J Subst Abuse Treat. 2008 Mar;34(2):147-56. Epub 2007 May 17.
Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption.
Ducharme LJ, Roman PM.
J Subst Abuse Treat. 2009 Jul;37(1):90-4. Epub 2008 Nov 11.
Policy progress for physician treatment of opiate addiction.
Merrill JO.
J Gen Intern Med. 2002 May;17(5):361-8.
Buprenorphine: a potential new treatment option for opioid dependence.
Srivastava A, Kahan M.
CMAJ. 2006 Jun 20;174(13):1835. No abstract available.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on